DelveInsight’s “Complicated Urinary Tract Infections – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Complicated Urinary Tract Infections, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Complicated Urinary Tract Infections Market Report:
• In 2023, the global market for Complicated Urinary Tract Infections (cUTIs) was valued at approximately USD 1.6 billion, with expectations for growth through 2034 during the study period (2020–2034) in the 7MM. This growth is driven by increasing incidence rates and the rise in antibiotic-resistant infections.
• In the 7MM, nearly 1 million cUTI cases progressed from uUTI in 2023, and this number is expected to rise during the forecast period (2024–2034), signaling a growing burden on healthcare systems worldwide.
• The United States accounted for about 42% of diagnosed cUTI cases in the 7MM in 2023, highlighting the significant healthcare burden in the region.
• On October 25, 2024, Iterum Therapeutics received FDA approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) to treat uUTIs caused by E. coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited oral antibacterial options. This approval marks Iterum’s first FDA-approved product and introduces a new treatment option for resistant uUTIs.
• In January 2024, TILITY therapeutics announced the FDA’s acceptance of its New Drug Application (NDA) for PIVYA (pivmecillinam) for the treatment of uncomplicated UTIs, a significant step in addressing the rising demand for new antibiotic treatments.
• Key drugs impacting the forecast period include Cefepime/enmetazobactam, Cefepime/taniborbactam, Cefepime/zidebactam, Nacubactam and cefepime or aztreonam, Tebipenem Poxil Hydrobromide, Imipenem/Cilastatin, XNW4107, and others. These drugs are expected to play a critical role in combating multidrug-resistant strains.
• Key companies in the cUTI market include Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Meiji Seika Pharma, Fedora Pharmaceuticals, Evopoint Pharmaceuticals, and others. These companies are at the forefront of developing novel therapies to address the growing challenge of cUTIs.
To Know in detail about the Complicated Urinary Tract Infections market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Complicated Urinary Tract Infections Market Forecast
Complicated Urinary Tract Infections Overview
Urinary tract infections (UTIs) are among the most common infectious diseases globally, yet they are often understudied. While uropathogenic E. coli (UPEC) is a major cause of UTIs, other bacteria can also infect the urinary tract, each interacting differently with the bladder environment.
UTIs vary in severity, from mild, uncomplicated infections to more serious conditions like complicated UTIs (cUTIs), pyelonephritis, and urosepsis. Proper stratification is crucial, as complicated UTIs are more likely to recur, become chronic, or lead to severe outcomes compared to uncomplicated ones. Host factors, rather than the pathogen itself, are key in the development and management of cUTIs and pyelonephritis. Additionally, high antibiotic resistance rates among causative microorganisms are often seen in more severe UTIs, complicating treatment.
Understanding the symptoms and causes of urinary tract infections is essential for distinguishing between uncomplicated and complicated cases.
Get a Free sample for the Complicated Urinary Tract Infections Market Report:https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Complicated Urinary Tract Infections Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Complicated Urinary Tract Infections Epidemiology Segmentation:
The Complicated Urinary Tract Infections epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Complicated Urinary Tract Infections Diagnosed Incident Cases
• Complicated Urinary Tract Infections Diagnosed Incident Cases of Progressed
• Complicated Urinary Tract Infections, Age-specific cases
• Pathogen-specific cases
• Total Complicated Urinary Tract Infections treated cases
Download the report to understand which factors are driving Complicated Urinary Tract Infections epidemiology trends @ Complicated Urinary Tract Infections Epidemiology Forecast
Complicated Urinary Tract Infections Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complicated Urinary Tract Infections market or expected to be launched during the study period. The analysis covers the Complicated Urinary Tract Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Complicated Urinary Tract Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Complicated Urinary Tract Infections Therapies and Key Companies
• Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics
• Cefepime-zidebactam (WCK-5222): Wockhardt
• Cefepime/Taniborbactam: Venatorx Pharmaceuticals
• Cefepime/Enmetazobactam: Allecra Therapeutics
• OP0595 (nacubactam): Meiji Seika Pharma/Fedora Pharmaceuticals
• XNW4107 (Imipenem/Cilastatin): Evopoint Pharmaceuticals
Complicated Urinary Tract Infections Market Strengths
• Ongoing R&D has led to novel antibiotics and non-traditional therapies, improving treatment efficacy and reducing resistance issues.
• Increasing cases, particularly among immunocompromised and elderly populations, drive demand for better diagnostic and therapeutic solutions.
Complicated Urinary Tract Infections Market Weaknesses
• The growing resistance to conventional antibiotics limits treatment effectiveness and increases the need for newer, more expensive alternatives.
• Stringent approval processes for new drugs and therapies slow market growth and delay patient access to innovative treatments.
Scope of the Complicated Urinary Tract Infections Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Complicated Urinary Tract Infections Companies: Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Meiji Seika Pharma, Fedora Pharmaceuticals, Evopoint Pharmaceuticals, and others.
• Key Complicated Urinary Tract Infections Therapies: Cefepime/enmetazobactam, Cefepime/taniborbactam, Cefepime/zidebactam, Nacubactam and cefepime or aztreonam, Tebipenem Poxil Hydrobromide, Imipenem/Cilastatin, XNW4107, and others.
• Complicated Urinary Tract Infections Therapeutic Assessment: Complicated Urinary Tract Infections currently marketed and Complicated Urinary Tract Infections emerging therapies
• Complicated Urinary Tract Infections Market Dynamics: Complicated Urinary Tract Infections market drivers and Complicated Urinary Tract Infections market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Complicated Urinary Tract Infections Unmet Needs, KOL’s views, Analyst’s views, Complicated Urinary Tract Infections Market Access and Reimbursement
To learn more about the key players and advancements in the Complicated Urinary Tract Infections Treatment Landscape, visit the Complicated Urinary Tract Infections Market Analysis Report
Table of Contents
1. Complicated Urinary Tract Infections Market Report Introduction
2. Executive Summary for Complicated Urinary Tract Infections
3. SWOT analysis of Complicated Urinary Tract Infections
4. Complicated Urinary Tract Infections Patient Share (%) Overview at a Glance
5. Complicated Urinary Tract Infections Market Overview at a Glance
6. Complicated Urinary Tract Infections Disease Background and Overview
7. Complicated Urinary Tract Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Complicated Urinary Tract Infections
9. Complicated Urinary Tract Infections Current Treatment and Medical Practices
10. Complicated Urinary Tract Infections Unmet Needs
11. Complicated Urinary Tract Infections Emerging Therapies
12. Complicated Urinary Tract Infections Market Outlook
13. Country-Wise Complicated Urinary Tract Infections Market Analysis (2020–2034)
14. Complicated Urinary Tract Infections Market Access and Reimbursement of Therapies
15. Complicated Urinary Tract Infections Market Drivers
16. Complicated Urinary Tract Infections Market Barriers
17. Complicated Urinary Tract Infections Appendix
18. Complicated Urinary Tract Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
